| Document |
Document Title |
|
JP2010215652A |
To provide one group of bicyclic heteroaryl substitution 6-alkylidene-penems which have beta-lactamase inhibiting properties and antibacterial properties.The present invention provides a compound shown by formula (I), pharmaceutical comp...
|
|
JP4553166B2 |
PCT No. PCT/GB96/01054 Sec. 371 Date Mar. 3, 1998 Sec. 102(e) Date Mar. 3, 1998 PCT Filed May 1, 1996 PCT Pub. No. WO96/34858 PCT Pub. Date Nov. 7, 1996Compounds, compositions, and methods of use as a pharmaceutical, where the compounds ...
|
|
JP2010119382A |
To provide a method for fluorescently labeling a protein labeling in vivo molecules.The method for fluorescently labeling the protein includes to obtain a fused protein of a target protein with a variant -lactamase and to fluorescently l...
|
|
JP2010518010A |
Compounds that inhibit cholinesterase activity and, upon hydrolysis release a pharmacologically active agent. The compounds of the invention are employed in methods to treat an individual. The pharmacologically active agent obtained by h...
|
|
JP2010047520A |
To provide a new compound useful as an antibiotic substance.The compound represented by formula (I), a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable ester thereof is provided.
|
|
JP4397435B2 |
Orally bioavailable prodrugs of sulopenem, e.g., and solvates and hydrates thereof, preparation thereof, formulation thereof, and use to treat and prevent infection in mammals such as humans. This abstract is not limiting to the invention.
|
|
JP4346528B2 |
A process for preparing a penicillanic acid compound of the formula (2) comprising reacting a halogenated penicillanic acid compound of the formula (1), (a) in the presence of a metal bismuth or bismuth compound, (b) with a metal having ...
|
|
JP4349913B2 |
The present invention provides a method for preparing a beta -lactam compound of the following Formula (3), which comprises the step of reacting a compound of the following Formula (1) with a trialkyl phosphite represented by the formula...
|
|
JP4326471B2 |
The present invention provides a method for preparing an organic compound, which comprises a dehydration step of distilling off water from a polar organic solvent solution containing the organic compound and water to bring the concentrat...
|
|
JP4275348B2 |
There is provided a method by which various compounds (1) having a carboxyl group in the molecule have the carboxyl group converted to a (dioxolenon-4-yl)methyl ester at low cost, in a simple way and at high yield. The process for pr...
|
|
JP4278182B2 |
The invention relates to a method for producing metal complex carboxylic acid amides characterized in that a metal complex carboxylic acid mixture consisting of metal complex carboxylic acid and at least one solubilizing substance is pre...
|
|
JP4213205B2 |
The invention relates to compounds of formula: wherein R1 is selected from the group consisting of fatty acid acyl groups of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, and wherein R2 is selected from the gro...
|
|
JP4158044B2 |
|
|
JP4138911B2 |
A process for preparing a beta -lactam derivative represented by the formula (2) A-COOH wherein A is a residue of the beta -lactam derivative, the process being characterized in that a beta -lactam derivative having a protected carboxyl ...
|
|
JP4111998B2 |
A back extraction process in which beta-lactam antibiotics or clavulanic acid is extracted from an organic solvent phase into an aqeous medium phase, using a mixing region in which the phases are mixed rapidly under high turbulence and s...
|
|
JP4104166B2 |
PCT No. PCT/EP96/04682 Sec. 371 Date Aug. 3, 1998 Sec. 102(e) Date Aug. 3, 1998 PCT Filed Oct. 28, 1996 PCT Pub. No. WO97/15579 PCT Pub. Date May 1, 1997A process for the production of a crystalline salt of amoxicillin utilizing ethanol ...
|
|
JP4100908B2 |
The present invention provides: an industrially-excellent and novel process for producing a basic antibiotic.inorganic acid salt, for example, an excellent production process for producing a hydrochloride thereof industrially, that is, a...
|
|
JP2008508243A |
The invention concerns an aminoquinoline-antibiotic hybrid compound of general formula (I): Q-(Y1)p-(U)p-(Y2)p-A: wherein Q represents an aminoquinoline, (Y1)p(U)p-(Y2)p'' is an optional spacer and A is an antibiotic residue. The inventi...
|
|
JP4050856B2 |
Procedure for the preparation of dioxopenicillanic acid derivatives and its salts pharmaceutically acceptable with general formula I, where, R is hydrogen, alkyl group containing 1 to 5 Carbon atoms or a residue of type -CH2R ', where R ...
|
|
JP3997436B2 |
Detectable compounds comprising a chemically-transformable first compound covalently linked to an electrochemiluminescent compound are provided. Such compounds are useful in processes and kits that monitor the status of the first compoun...
|
|
JP2007246514A |
To provide a novel crystal of piperaccillin sodium having a pharmaceutically excellent effect, and a preparation for use in powder-filled injection filled with the same. A novel crystal of piperacillin sodium having a diffraction angle o...
|
|
JP2007231020A |
To provide a new compound which improves the lipid barrier penetrability of a biologically active substance comprising a fatty acid such as lipoic acid and simultaneously makes a biologically active substance comprising a different fatty...
|
|
JP3970340B2 |
PURPOSE: To efficiently remove silyl group of a silyl ether compound unstable under strongly acidic or basic condition by using a safe and inexpensive hydrofluoric acid salt of an amine in an organic solvent. CONSTITUTION: Silyl group is...
|
|
JP3960481B2 |
The invention relates to compounds of formula: wherein R1 is selected from the group consisting of fatty acid acyl groups of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, and wherein R2 is selected from the gro...
|
|
JP2007176939A |
To provide a detectable compound comprising a first compound which is bonded to an electrochemiluminescent compound by a covalent bond and chemically transformable.The compound is used for measuring the object to be analyzed in a sample ...
|
|
JP2007131535A |
To provide an agent for suppressing the formation of a modified protein, free from hypotensive action and inducing no vitamin B6 deficiency.The agent for suppressing the formation of a modified protein uses a compound having a free or sa...
|
|
JP2007099763A |
To provide a new crystal of piperacillin sodium-1 hydrate, to provide a method for producing the crystal, and to provide a medicinal preparation for injection, packed with powder thereof.The new crystal of piperacillin sodium-1 hydrate, ...
|
|
JP3866298B2 |
Compounds of formula I: wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting beta-lactamase enzymes, for enhancing the activity of beta-l...
|
|
JP2006526612A |
Prodrugs of 6-beta-hydroxymethylpenicillanic acid sulfone having the structure wherein R is H or methyl, each X is methylene, and Y is O, or wherein R is H, each X is O and Y is methylene, and solvates thereof are disclosed. Also disclos...
|
|
JP3836675B2 |
A method for preparing an alpha-oxolactam comprising, reacting a corresponding alpha-diazolactam with an oxygen donor, in the presence of a transition metal catalyst, to yield the corresponding alpha-oxolactam.
|
|
JP2006176427A |
To provide an estrone 3-sulfate transporter activity inhibitor or breast cancer cell proliferation inhibitor or breast cancer curative, with no need of being taken in cells, good in drug delivery tendency and extremely slight in side eff...
|
|
JP2006515633A |
A pharmaceutically active compound having a carboxylic acid group -COOH as a part of its chemical structure which -COOH group is in the form of a carboxylic acid ester.
|
|
JP3775818B2 |
PURPOSE: To obtain in high yield and purity the subject compound in safe and simple operation by substituting a halogen or an eliminable group for the hydroxyl group of a halogenated β-lactam compound. CONSTITUTION: A halogenating agent...
|
|
JP2006508984A |
A method and compositions for treating persistent pulmonary hypertension in human newborns that deploys an intravenous infusion of a modified drug formed by adding one or more of a predetermined chemical arrangement to an efficacious par...
|
|
JP2006508985A |
A method for modifying at least one non-ester-containing parent compound, and the compounds produced using such method, which compounds are deployed to temporarily incapacitate at least one subject are disclosed. The modified compounds a...
|
|
JP2006034950A |
To provide a method and an agent for efficiently cleaning an institution and/or facilities used for manufacturing a substance capable of chemically reacting with a nucleophilic agent and/or a medicine.This is a method for cleaning an ins...
|
|
JP3743823B2 |
To provide a TMPB substance excellent in stability without danger of quality deterioration due to decomposition even after storage for a long time at room temperature. The TMPB substance of the present invention is a crystal of 2-methyl-...
|
|
JP3743822B2 |
The crystal of the invention is crystal of diphenylmethyl 2-methyl-2-triazolylmethylpenam-3-carboxylate which is stable substantially without decomposition or degradation of properties even when left to stand at room temperature for 1 ye...
|
|
JP2005539037A |
Prodrugs of 6-beta-hydroxymethylpenicillanic acid sulfone having the structure wherein R is H or methyl, and solvates thereof, are disclosed. Also disclosed are pharmaceutical compositions comprising a prodrug of the present invention or...
|
|
JP2005534662A |
The present invention relates to a process for preparing 2alpha-methyl-2beta-substituted methyl penam derivatives from cepham derivatives, more particularly the present invention provides a novel process for preparing 2beta-heterocyclyl ...
|
|
JP2005525399A |
Compounds of formula (I): wherein R1, R2, R3, R4 and n have any of the values defined in the specification, and their pharmaceutically acceptable salts, are useful for inhibiting simultaneously serine and metallo-beta-lactamase enzymes, ...
|
|
JP2005524519A |
Small crystals are made by mixing a solution of a desired substance with an anti-solvent in a fluidic vortex mixer in which the residence time is less than 1s, for example 10 ms. The liquid within the fluidic vortex mixer ( 12 ) is subje...
|
|
JP2005523937A |
The present invention provides a process of making compounds of formula I, which are useful for the treatment of bacterial infection or disease.
|
|
JP3636207B2 |
PURPOSE: To provide an immune-activating and infection-preventing agent safe for men and animals, and also to provide a method for producing the same. CONSTITUTION: An immune-activating and infection-preventing agent comprises riboflavin...
|
|
JP2004528282A |
The present invention relates to novel triazene compounds, their use and novel alkylation methods. The trizen compound has the general formula XYZN = N-NH-R (in the formula, X = insoluble support, Y = atom or atomic group functioning as ...
|
|
JP3532224B2 |
PURPOSE: To enable efficient and inexpensive removal of silyl groups by reaction of a specific silyl ether compound with an inorganic acidic fluoride in the presence of a quaternary ammonium salt, in the production of a specific compound...
|
|
JP3522758B2 |
A process for the preparation of a compound of formula (IVA) which process comprises subjecting a compound of formula (V), where R is an ester-forming group or carboxy-protecting group, and X and Y are hydrogen or halogen provided that a...
|
|
JP3523664B2 |
PURPOSE: To obtain a new compound, capable of manifesting excellent antimicrobial activity against Pseudomonas aeruginosa, stable to β-lactamases, having strong antimicrobial activity even against resistant bacteria and useful as an ant...
|
|
JP2004512255A |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
|
JP2004501619A |
A process for the preparation of biologically active compounds, wherein active substances having additional functional groups and a modified spectrum of activity and modified application properties are obtainable from medicinal substance...
|
